Skills this job asks for
LeadershipLogisticsRisk management
Add your CV (free) to see which of these your CV is missing.
Sponsorship verdict
Sponsorship possible
One solid signal, not two. Worth applying, and worth asking about sponsorship early.
-
✓
Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first.
-
?
The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
-
?
No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
-
✓
What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles15 certified filings for “Associate Director Oncology Outcomes Research” (Medical Scientists, Except Epidemiologists) in MD: $126k–$185k, median $140k.
-
✓
Confirmed live todayWhen a source last listed this job as open.
Details and sources
- Employer is on a government sponsor record
- The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
- No salary bar for this route
- H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles
- 15 certified filings for “Associate Director Oncology Outcomes Research” (Medical Scientists, Except Epidemiologists) in MD: $126k–$185k, median $140k. Most were filed at wage level II (47%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.
About the role
At AstraZeneca, we are building the supply capabilities needed to deliver the next generation of cell therapies to patients around the world. As Senior Director, Delivery, you will lead the global enabling team responsible for strengthening and protecting the third-party supplier ecosystem across our Cell Therapy portfolio.
You will shape how we anticipate supplier risk, build strategic supplier relationships and secure the direct materials and external capabilities needed to support in-vivo, autologous and allogeneic cell therapies. Your leadership will help move the organization from reactive escalation toward proactive supply assurance, creating resilient, scalable supply networks that can grow from clinical development through commercial delivery.
Based in Gaithersburg Maryland, this role reports to the Executive Director, External Supply & Delivery and includes global travel to suppliers as needed.
Why This Role
Cell therapy supply chains operate with extraordinary complexity. Materials, manufacturing partners, logistics providers and technology platforms must perform reliably against highly regulated requirements and patient-critical timelines.
In this role, you will have the opportunity to:
• Build the Supplier Relationship Management (SRM) and supplier risk frameworks that shape how Cell Therapy manages its global external ecosystem.
• Provide forward-looking visibility of supplier and supply continuity risks across the Cell Therapy portfolio.
• Strengthen strategic partnerships with critical suppliers and prepare the supplier network for global commercial scale.
• Improve on-time, in-full (OTIF) performance and reduce the risk of patient-impacting supply disruptions.
• Advance dual-sourcing, business continuity, supplier development and new material introduction strategies.
• Use analytics, digital capabilities and AI to strengthen risk monitoring, supplier performance and supply assurance.
• Develop a global team with expertise spanning supplier risk, SRM, direct materials and supply assurance.
Accountabilities
Supplier Risk & Portfolio Resilience
• Develop, own and continuously improve the Risk Framework for External Supply & Delivery, including supplier risk assessment, risk taxonomy and scoring, mitigation standards, escalation triggers, business continuity and contingency planning.
• Lead risk management at the Cell Therapy Technical Operations (CTTO) portfolio level, maintaining consolidated, forward-looking visibility across CDMOs, direct materials, equipment and services, and logistics suppliers.
• Lead strategies addressing single-source dependencies, dual sourcing, alternate supplier identification, new material introduction (NMI) and product lifecycle risk.
• Strengthen resilience for critical plasmids, raw materials, cold chain and other supply dependencies.
• Maintain visibility of supplier sub-tier (n-1), geopolitical and China-related supply risks, including relevant BIOSECURE considerations.
• Drive mitigation actions to closure in partnership with External Supply, Quality, Planning and other stakeholders.
Supplier Relationship Management
• Develop and lead the enterprise Supplier Relationship Management (SRM) framework, including supplier segmentation, governance, service-level agreement (SLA) performance, scorecards, quarterly business reviews and continuous improvement.
• Establish and govern the Preferred Supplier List (PSL), helping identify suppliers positioned to support future clinical and commercial requirements.
• Establish expectations for root-cause analysis and corrective and preventive action (CAPA) within supplier performance management.
• Build consistent supplier performance dashboards covering portfolio health, on-time delivery, quality events, value delivery and s
Apply on employer site ↗